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Abstract 
Many concepts have been devised for the treatment of late periprosthetic infections of total 
hip prostheses. A two-stage revision with a temporary antibiotic-impregnated cement spacer 
and a cemented prosthesis appears to be the most preferred procedure although, in recent 
times, there seems to be a trend towards cementless implants and a shorter period of anti-
biotic treatment. Because of the differences in procedure, not only between studies but also 
within studies, it cannot be decided which period of parenteral antibiotic treatment and 
which spacer period is the most suitable. The fact that comparable rates of success can be 
achieved with different treatment regimens emphasises the importance of surgical removal 
of all foreign materials and the radical debridement of all infected and ischaemic tissues and 
the contribution of these crucial procedures to the successful treatment of late peripros-
thetic infections. 
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Introduction 
Periprosthetic infections occur with an incidence 
of less than 1% of patients but nevertheless are a se-
rious complication of hip arthroplasties [1,2]. When 
early infections occur, within 4 weeks of implantation, 
the implant can be left in place with a high probability 
of cure whereas late infections require prosthesis re-
vision to eradicate the infection [3,4]. In such cases, 
one can differentiate between one-stage and two-stage 
revisions. In the former a new prosthesis is implanted 
immediately after the removal of all foreign material 
in one operation. Two-stage revision involves an ini-
tial operation to remove all foreign materials and this 
is followed by an interim phase of 6 – 10 weeks, either 
left as a Girdlestone situation or with the implantation 
of a cement spacer. Individual aspects of both forms 
of revision have been treated very differently in the 
past so, in the following paragraphs, the different 
concepts are summarized and their respective ad-
vantages and disadvantages discussed. 
One stage revision 
The advantage of the one-stage revision is that 
only one operation is required and functional prob-
lems associated with a Girdlestone situation, such as 
leg shortening and instability, or, in the case of a ce-
ment spacer, spacer fracture, abraded particles from 
the spacer or bone resorption, can be avoided. Most 
surgeons have used bone cement laden with antibiot-
ics during the re-implantation whereby the antibiotic 
contained in the cement or added to it is specific for 
the pathogen involved [5-7]. A prerequisite for this 
procedure is the isolation of the organism(s) from Int. J. Med. Sci. 2009, 6 
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previously obtained aspirated fluid or biopsied mate-
rial and the determination of their antibiotic suscepti-
bility so that an organism-specific mixture of antibi-
otics can be added to the bone cement and a specific 
local antibiotic treatment initiated [5,6]. Here it is 
necessary for the fluid or tissue sample to be incu-
bated for 14 days [6,8,9]. This long incubation period 
is necessary because the pathogens causing the pe-
riprosthetic infection usually occur in very small 
numbers in the form of a biofilm and are also often in 
a sessile state that is characterized by a slow rate of 
reproduction [8,10-13]. An analysis we carried out of 
110 infected hip and knee endoprostheses showed 
that the culture detection rate after 7 days, the longest 
incubation period reported in most studies, was a 
mere 73.6%. To identify all infections it was necessary 
to cultivate for 13 days [14]. If the incubation period is 
of sufficient duration an accuracy of approximately 
90% can be achieved with the aspiration method 
[15,16]. We believe that a lack of sufficient incubation 
led to the poor sensitivity of the pre-operative aspira-
tion reported in other studies (for example, 46.1% 
reported by Hoffmann et al. [17]). The degree of suc-
cess of one-stage revision of prostheses with antibiot-
ics added to the cement led to 88% eradication re-
ported by Steinbrink et al. [6], to 91% reported by 
Wroblewski et al. [7] and to 93,7% in a newer report 
by Rudelli et al. [18].  
Mixing antibiotic into the cement affects the 
quality of the cement, which is why only antibiotic 
powder to a maximum of 10% of the total cement 
amount should be used [19]. Not all antibiotics can be 
used because they have to be available in powder 
form, be water-soluble and be thermostable. The most 
commonly used are gentamicin, clindamycin, van-
comycin, tobramycin, aztreonam, ampicillin and 
ofloxacin [1,19-21]. There is little data available that 
addresses the release of antibiotics from spacers in 
vivo over a period of several weeks although the level 
of released antibiotic has been suggested by several 
authors to be sufficient for at least 4 months [21-23]. 
Furthermore, it has been found that the antibiotics 
affect each other's elution from the cement whereby 
the use of two antibiotics results in a synergistic effect 
and the release of the individual components is higher 
than that of the single antibiotics on their own [24-28]. 
It has also been demonstrated that the elution of anti-
biotic from hand-mixed cemen t  i s  h i g h e r  t h a n  t h a t  
from cement mixed under vacuum because of the 
presence of air bubbles and their greater surface area. 
However the mechanical characteristics of 
hand-mixed cement are not as good [19].  
Some newer studies of one-stage cementless re-
vision of septic prostheses described the use of can-
cellous allografts that had been impregnated with 
antibiotics. Winkler et al. [29] reported 37 such cases 
of one-stage cementless revisions and demonstrated 
an eradication rate of 92% after a follow-up period of 
4.4 years. 
A one-stage revision can be indicated irrespec-
tive of the concept involved when a microorganism 
has been identified but spacer implantation is not 
possible because of a severely defective acetabulum 
and a Girdlestone situation is undesirable. 
Two-stage revision 
Two-stage septic revision surgery is the most 
common method for treating infected endoprostheses. 
A general advantage of the two-stage concept is that 
the surgical debridement is carried out twice whereby 
the second operation allows for the eradication of 
residual organisms following the initial debridement. 
The cement of the spacer is not intended as a means of 
fixing the prosthesis so the mechanical characteristics 
of the cement is not of primary importance at this 
stage. Thus, large amounts of antibiotics can be mixed 
into the cement before the spacer is formed. It has 
been possible to achieve a survival rate using 
two-stage revision concepts for infected hip arthro-
plasties of between 90% and 100% [1,30-32]. 
In most two-stage revisions an antibi-
otic-containing spacer is usually placed in position for 
a certain period of time before the final prosthesis is 
implanted [17,20,30,33,34]. The function of the spacer 
is on the one hand to release the antibiotic into the 
infected bed of the prosthesis and on the other to 
minimize soft-tissue contractures, retain soft tissue 
tension and so maintain reasonable functionality until 
a prosthesis can be re-implanted [30]. There are sev-
eral different types of spacer: monoblock and 
two-part spacers, commercially available and cus-
tomized spacers made in the operating theatre. The 
potential disadvantages of the monoblock spacers are 
spacer fracture and bone resorption while the 
two-part spacer can produce abraded cement particles 
[35-37]. In order to avoid spacer fractures we use a 
two-part spacer where the cup-shaped acetabulum 
spacer is formed out of antibiotic loaded cement (with 
a specific mixture of antibiotics recommended by the 
microbiologist). The spacer stem component consists 
of old prosthesis stem models, monoblock devices in 
most cases and no longer used for primary implanta-
tions, that are encased in antibiotic-supplemented 
cement and, just before implantation, coated in the 
patient's own blood in order to facilitate easier re-
moval. The two spacer components are connected by 
a metal headpiece (Figure 1) [20]. However, a recent 
analysis of synovial membranes obtained during the Int. J. Med. Sci. 2009, 6 
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operation to remove the spacer and to implant the 
new prosthesis revealed the presence of abraded ce-
ment debris, in particular, zirconium dioxide particles 
[unpublished data]. 
 
 
Figure 1: Radiograph of a hip spacer of a 63year old man 
with late periprosthetic infection of the left hip 
 
Another concept involves the use of antibi-
otic-laden beads although a disadvantage of this 
procedure is that ready-manufactured beads are usu-
ally employed and these only contain gentamicin or 
vancomycin [38,39]. Leg shortening and instability 
still occur and cause problems with mobilization. 
Re-implantation of a prosthesis is also often made 
more difficult because of scarring, tissue shrinkage 
and osteoporosis caused by inactivity [37,40,41]. In 
addition, abrasion of zirconium dioxide particles is to 
be expected during mobilization and this could lead 
to third-body-wear following re-implantation of the 
prosthesis. Disch et al. [35] decided therefore not to 
use local antibiotic carriers following removal of the 
prosthesis during two-stage revisions and found a 
reinfection rate of 6.3% in 32 hips and 41.3 months 
after re-implantation although there was a consider-
able reduction in the quality of life during the Girdle-
stone phase which lasted 13 months on average. 
There are many questions pertaining to both 
one-stage and two-stage revisions that still have to be 
answered and existing procedures are based more on 
empirical findings than on data from prospective 
studies with a high level of evidence. It is for this 
reason that the following aspects of two-stage revision 
have been treated very differently by different groups: 
the type of antibiotic used in the spacer, the duration 
of the spacer period, the duration of systemic antibi-
otic treatment, aspiration before re-implantation and 
the type of re-implantation (cemented or cementless). 
Type of antibiotic used in the spacer 
Most published studies always include the same 
antibiotics in the cement. Some authors use vanco-
mycin and tobramycin as local antibiotics on a regular 
basis because they have a broad spectrum of activity 
[38,42]. However, not all bacteria can be successfully 
treated with these agents (e.g., some gram-negative 
organisms), so this is an argument for investigating 
the antibiotic resistance pattern of the isolated bacteria 
and selecting a specific antibiotic for the treatment. 
Masri et al. [43] reported a success rate of 89.7% in 
their retrospective study involving bacteria-specific 
antibiotic mixed into the cement of a PROSTALAC® 
spacer (DePuy Orthopaedics, Inc, Warsaw, IN) and 
we saw no reinfection of 36 cases with a minimum 
follow-up of 2 years using this concept for handmade 
spacers [20].  
Duration of antibiotic treatment 
While most authors carry out a 6 week period of 
intravenous antibiotic therapy, there is a great variety 
of treatment regimens (Tables 1 and 2). In more recent 
studies, very much shorter periods of antibiotic 
treatment have been employed. Whittaker et al [44] 
reported a 92.7% eradication of infection for 41 
re-implanted hip endoprostheses over a follow-up 
period of 4 years following a short, intravenous 
treatment with vancomycin alone in combination 
with cement spacers containing vancomycin and 
gentamicin. McKenna et al. [45] only found one rein-
fection after an average of 35 month's follow-up of 30 
patients with infected hip arthroplasties who as part 
of the two-stage revision procedure, only received a 5 
day systemic treatment with antibiotics. The design of 
the antibiotic administration after re-implantation of 
the prosthesis is even more variable and range from 
no antibiotic treatment at all to three months of 
post-surgery treatment (Tables 1 and 2).   
The fact that there are differences in procedure 
not only between studies but also within studies 
means it cannot be decided which period of par-
enteral antibiotic treatment is the most suitable. That 
different durations of antibiotic therapy lead to simi-
lar clinical results emphasizes the fact that treatment 
with antibiotics is only a form of support therapy for 
the periprosthetic infection and that the crucial fea-Int. J. Med. Sci. 2009, 6 
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tures of all concepts are the rigorous surgical removal 
of foreign material and the radical debridement of all 
infected and ischaemic tissues. These procedures are 
vital for the success of the revision process. However, 
in cases of haematogenous infection the systemic an-
tibiotic therapy is essential for treating the focus and 
preventing of septic metastases.  
Duration of the spacer period and antibiotic 
therapy 
The period of time between the two operations 
of a two-stage revision is also very variable, ranging 
from a few days to several years (Tables 1 and 2). 
Many authors determine the time of re-implantation 
of a prosthesis according to clinical parameters and 
clinical chemistry data and carry out an aspiration of 
the area before surgery is carried out [32,36,43,46]. 
Other authors have a more or less rigid procedural 
plan [31,33,39]. These differences in procedure,  not 
only between studies but also within studies, means 
that it cannot be decided which time period between 
the two steps and spacer period is the most suitable. 
This also appears to underscore the importance of the 
surgical debridement for therapeutic success of the 
two-stage revision. 
Aspiration before re-implantation 
Many authors recommend aspiration before the 
re-implantation operation in order to check whether 
or not the joint is free of infection [43,47]. The disad-
vantage of this concept is that the second aspiration 
requires a pause in the antibiotic therapy for at least 2 
weeks, if not 4 weeks [48]. This is then followed by a 
2-week incubation period so the second operation can 
be delayed by up to 4 or 6 weeks. Moreover, the local 
levels of antibiotic released by the spacer would likely 
influence the detection of viable bacteria [3]. For these 
reasons we do not perform an aspiration before 
re-implantation and rather make a decision based on 
clinical findings and CRP values as described by 
Hsieh et al. [41,49]. 
Cemented re-implantation 
The fixation method chosen for the final pros-
thesis in the two-stage technique usually involves the 
use of cement because this allows the surgeon to add 
antibiotics to the cement to help prevent recurrent 
infection [1,31-33,50]. Rates of eradication between 
84% and 100% have been described for this procedure 
(Table 1). 
Table 1: Results of two-stage cemented revision of periprosthetic infection of the hip.  
Author N  Fol-
low-up 
Spacer/ 
Beads 
Local 
anti-biotics 
Duration of 
intravenous 
antibiotics 
Interval until 
re-implan-tation
Antbiotics 
after im-
planta-tion 
Eradi-cation 
rate 
Aseptic loos-
ening 
McDonald 
[46]  
82 5.5  years  Resection 
arthroplasty 
No  26.1 (4 – 59 
days) 
1.5 years (6 days 
– 6.2 years) 
 No antibiot-
ics in cement 
87 %   n.r. 
Colyer [51]  37  2.7 years  Resection 
arthroplasty 
No  6 weeks par-
enteral 
6 weeks (4 – 214 
weeks) 
2 weeks par-
enteral, 3 
months oral 
84 %  n.r. 
Garvin [31]  32  ≥ 2 years, 
4.1 years 
Beads  Gentamicin  6 weeks par-
enteral 
6 weeks   n.r.  91 %  0 % 
Lieberman 
[32] 
32 40 
(24-80) 
mo 
Beads 
Spacer 
Gentamicin 
Tobramycin 
Vancomycin 
6 weeks (20 – 49 
days) 
8,8 weeks (3 
weeks – 32 
months) 
 n.r.  91 %   n.r. 
Younger [52]  48  43 
(24-63) 
mo 
Spacer  Gentamicin  3 weeks par-
enteral, 3 weeks 
oral 
13 weeks (5 – 42 
weeks) 
3 weeks par-
enteral, 3 
weeks oral 
94 %  0 % 
Leunig [37]  12  2.2 years  Spacer  Gentamicin  n.r.  4 (2-7) months    100 %  n.r. 
Evans [33]  23    Spacer  Gentamicin  6 weeks  12 weeks  No  95.7 %  n.r.  
Hsieh [36]  24  4.2 years  Spacer  Specific: 
Vancomycin 
Piperacillin 
Aztreonam 
Teicoplanin 
 
2 weeks par-
enteral,  
4 weeks oral 
11 – 17 weeks, 
when CRP 
normal 
1 week par-
enteral  
 
100 %  0 % 
 
Cementless re-implantation 
The disadvantage of the cemented revision 
technique is related to the fact that the osseous bed of 
the prosthesis has not only been enlarged by the 
loosening of the primary prosthesis but also become 
thinner and sclerotic. This reduces the ability of the 
cement to adhere to the bone. Dohmae et al. [53] re-
ported the resistance of the bone-cement interface to 
shear force-related failure is reduced by 79% when 
comparing a cemented revision implant to a cemented 
primary implant. Wirtz and Niethard [54] reported a 
higher revision rate associated with aseptic loosening 
of cemented revision prostheses compared to ce-
mentless components (i.e., 15.1% versus 4.3% for the 
acetabular cup and 12.7% versus 5.5% for the stem). 
Therefore, the advantage of cementless revision may 
also exist for implant fixation in two-stage septic re-Int. J. Med. Sci. 2009, 6 
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visions although exact data concerning mid- and 
long-term survival rates of cemented and cementless 
implants in septic revision are rare in the literature 
[40]. Sanchez-Sotelo et al. [55] reported a 10-year in-
fection-free survival rate of 87,5% and a mechanical 
survival rate of only 75,2% for re-implanted femoral 
components mostly fixed with cement.   
Nevertheless, because the use of cementless 
components at the second stage does not allow the 
surgeon to add local antibiotics to the cement to help 
prevent recurrent infection, there is some concern that 
recurrent infection rates will be higher with cement-
less fixation [50,56]. A few retrospective studies have 
reported promising results with two-stage revision 
operations using cementless implants with rates of 
eradication between 82% and 100% (Table 2) 
[38,39,43,56-59].  
 
 
Table 2: Results of two-stage cementless revision of periprosthetic infection of the hip. 
Author N  Fol-
low-up 
Spacer/ 
Beads 
Local 
anti-biotics 
Duration of 
intravenous 
antibiotics 
Interval until 
re-implan-tation
Antibiotics 
after im-
planta-tion 
Eradi-cation 
rate 
Aseptic loos-
ening 
Wilson [56]  22/ 
13** 
≥ 3 years, 
48 
months 
Resection 
arthroplasty 
no  3 weeks par-
enteral 
6-12 weeks  3 days par-
enteral 
91 % /  
100 % ce-
mentless 
7.6 % stem 
loose 
Nestor [58]  34  47 
(24-72) 
mo 
Resection 
arthroplasty 
no  ≥ 4 weeks par-
enteral 
8 (3-19) months different  82 %  18% stem 
loose 
Fehring [38]  25  41 
(24-98) 
mo 
Beads Tobramicin  in 
16 cases 
6 weeks par-
enteral 
4.8 months    92 %  0 % 
Haddad [39]  50  5.8 
(2-8.7) 
years 
Beads + ce-
ment ball 
Gentamycin  5 days par-
enteral and than 
oral 
3 weeks  ≥ 3 months  92 %  8% stem 
subsidence 
Koo [57]  22  41 
(24-78) 
mo 
Spacer 
Beads 
Vancomycin 
Gentamicin 
Cefotaxime 
6 weeks  6-12 weeks  n.r.  95 %  5%cup loose 
30% stem 
subsid. 
Hofmann 
[17] 
27 76 
(28-148) 
mo 
Old stem and 
new poly-
ethy-lene cup 
Tobramicin  6 weeks par-
enteral, in 17 
cases additional 
oral for 6 weeks
n.r.  n.r.  94 %  0 % 
Kraay [42]  33  ≥ 2 years  Spacer in 16 
cases 
Tobramicin in 
16 cases 
≥ 6 weeks par-
enteral 
7.4 (3-37) 
months 
n.r.  92 %  9 % cup 
0% stem 
Masri [43]  29  ≥ 2 years  Prostalac 
spacer 
Tobramicin 
Vancomycin 
Cefuroxime 
Penicillin* 
 
6 weeks par-
enteral or in 
combina-tion 
with oral 
12 weeks  5 days in-
tra-venous 
90 %  0 % 
Yamamoto 
[60]  
17 38  mo  Spacer  Gentamicin 
Vancomycin 
> 3 weeks  n.r.  1 week par-
enteral, oral 
until CRP 
normal 
100 %  n.r. 
Fink [20]  36  ≥ 2 years  Spacer  Specific: 
Gentamicin 
Clindamycin 
Vancomycin 
Ampicillin 
Ofloxacin 
2 weeks par-
enteral,  
4 weeks oral 
6 weeks  2 weeks par-
enteral,  
4 weeks oral 
100 %  6% stem 
subsidence 
0% 
loose-ning 
* = combination of another local antibiotic with tobramycin, mo = months, ** = 13 of 22 re-implantations without cement; stem subsid = stem 
subsidence; nm = non-modular; pf = proximal fixation 
 
 
Some reports describe the stability of cementless 
fixation after septic revision surgery using mostly 
non-modular implants: Fehring et al. [38] achieved 
stable bone-ingrown fixation in 96% of their cases 
using non-modular and modular cementless pros-
theses with proximal fixation, while Nestor et al. [58] 
reported an implant stability of 79% using 
non-modular, proximal porous-coated stems. Wilson 
and Dorr [56] on the other hand, only achieved a 38% 
bone-ingrown fixation after 3 years in, admittedly, a 
small group of 13 patients using a cementless 
non-modular stem with proximal fixation. Moreover, 
the rate of early loosening of cementless revisions 
stems varies from 0% to 18% (Table 2). We found low 
rates of subsidence (6%) and loosening (0%) and a 
high rate of bone-ingrown fixation (94%) of a ce-
mentless modular revision stem system (Revitan 
curved, Zimmer GmbH, Winterthur, Switzerland), 
which we believe is due to the distal fixation proce-
d u r e s  i n  v i a b l e  b o n e  o n  t h e  o n e  h a n d  a n d  t o  t h e  Int. J. Med. Sci. 2009, 6 
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modularity of the stems on the other hand [20] (Figure 
2). Thus, as already described in an anatomic study, 
the in situ assembly of the components enabled the 
effective distal fixation of the distal prosthetic com-
ponent in an adequate osseous bed before the proxi-
mal component is added and corrected for leg length 
and antetorsion [61]. 
 
 
Figure 2: Radiograph two years after re-implantation of a 
cementless modular revision stem and a press-fit-cup 
 
Allografts 
In septic revision major bone loss presents a dif-
ficult problem for reconstructive surgery. One possi-
bility is to restore the bone defects using allografts. 
Many studies on allografts in septic two-stage revi-
sion do not provide enough evidence for a valid con-
clusion to be drawn because they include the treat-
ment of patients with both structural and morselized 
allografts (e.g. in the form of an impaction graft) that 
are biologically very different with respect to poros-
ity, vascularisation and incorporation. However, they 
have shown re-infection rates between 9% and 14% 
[47,62,63]. 
The advantages of the use of large allografts in-
clude the restoration of depleted bone stock, the cor-
rection of leg-length discrepancy and the ability to use 
conventional revision prostheses (and not megapros-
theses). The preservation of the soft-tissue envelope 
including the greater trochanter and its reattachment 
to the allograft allows restoration of abductor function 
[64, 65]. The disadvantage of its use is at first the risk 
of infection because allografts are non-vascularised 
osseous segments and may represent a potential se-
questrum [66,67]. However, in two-stage revisions 
Hsieh et al. [36] reported no recurrence of infection in 
24 patients after a mean follow-up of 4.2 years and 
Ilyas et al. [65] in 10 patients after a mean follow-up of 
5 years. Allexeeff et al. [64] also reported no recur-
rence of infection and only one graft failure after a 
mean follow-up of 47.8 months in 11 cases with 
two-stage revisions. They advocate structural al-
lografts only in two-stage revisions with an interval 
before re-implantation of three months for 
Gram-positive and of six months for Gram-negative 
organisms or polymicrobial infections. English et al. 
[68] reported a success rate of 93% in the elimination 
of infection at a mean follow-up of 53 months in 53 
patients.  Buttaro et al. [69] used vancomy-
cin-impregnated morselized allografts for impaction 
grafting in two-stage revision and saw a reinfec-
tion-rate of 3.3 % in 29 cases after a mean follow-up of 
32.4 months.  
Whereas Winkler et al. [70] used morselized al-
lografts with local antibiotic impregnation, Rudelli et 
al. [18] did not impregnate with antibiotic during 
one-stage septic revisions and achieved success rates 
of 92% and 93.7% after 4.4 and 8.6 years respectively. 
The relatively few in vitro and in vivo studies of 
the release of antibiotics from allografts indicate that it 
is possible to achieve high local concentrations of an-
tibiotics with this technique, some reporting concen-
trations up to many times the minimal inhibitory 
concentration of the antibiotic concerned [70,71]. 
However, further study is required in order to deter-
mine the duration of antibiotic release in vivo from 
such allografts before a final assessment of the tech-
nique can be made.  
Our own concept 
We carry out two-stage revisions with cement-
less hip prostheses (Figures 1,2). Our technique differs 
from previously published techniques with cement-
less two-stage revision surgery in four ways (Table 2). 
Firstly, the antibiotic used in the antibiotic-loaded 
cement of the spacer and used for the systemic treat-
ment is chosen on the basis of the sensitivity of the 
bacterium causing the infection. Since the use of sev-
eral antibiotics seems to result in synergistic effects 
with regard to local release patterns, we always use at 
least two antibiotics in the cement and prefer COPAL® 
cement to Palacos® R-G cement (Heraeus Medical, 
Wehrheim, Germany) whenever possible because the 
former exhibits better release of gentamicin [27]. Sec-
ondly, we employ a short period of 2 weeks of intra-Int. J. Med. Sci. 2009, 6 
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venous antibiotic treatment. Thirdly, re-implantation 
is performed after a 6 week spacer interval and 
fourthly, we use modular revision stems with distal 
fixation in the femoral diaphysis. In a prospective 
study using this standardized protocol for two-stage 
cementless revision of periprosthetic infection of hip 
prostheses we were able to demonstrate 100 % eradi-
cation of infection [20]. We achieved implant stability 
with no early aseptic loosening, bone-ingrown fixa-
tion in 94% of the stems and absence of stem subsi-
dence in 94%, as well as Harris hip scores of 90 points 
resulting in the conclusion that this concept is suffi-
cient for treatment of periprosthetic late infections of 
hip prostheses [20].  
The 2-week period of parenteral antibiotics we 
use appears short. It is, however, consistent with the 
recommendations of Zimmerli et al. [72,73] and 
Trampuz and Zimmerli [74] and has been used in 
other studies, e.g., Hsieh et al. [49] with 95% eradica-
tion [41,75]. Also, the total duration of antibiotic 
treatment of 3 months in our study was consistent 
with the recommendations of Zimmerli [73] and 
Trampuz and Zimmerli [74]. The 6-week spacer pe-
riod in our study is also short but has been used by 
other authors (Table 1,2). 
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